[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"appetite-regulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:appetite-regulation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,87,117,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643605","satiety-evaluation-of-mature-okra-flour-incorporated-biscuit-100643605",false,"NCT07631663","Satiety Evaluation of Mature Okra Flour-incorporated Biscuit","Evaluating the Impact of Mature Okra Flour-Incorporated Biscuits (MOFB) on Perceived Satiety Through the Satiety Labeled Intensity Magnitude (SLIM) Scale and Metabolomic Approach","MOFB","Inclusion Criteria:\n\n* Young adults aged between 18 and 39 years.\n* Normal Body Mass Index (BMI).\n\nExclusion Criteria:\n\n* Smokers.\n* Pregnant or lactating women.\n* Individuals with daily medication prescriptions for chronic metabolic conditions, cardiovascular management, or hormonal regulation.\n* Use of daily medications\u002Fsupplements that influence appetite regulation, metabolic signalling, or systemic metabolomic profiles, including:\n\n  1. Hormonal contraceptives, glucocorticoids, and oral\u002Finjectable anti-obesity medications (e.g., GLP-1 agonists).\n  2. Antihypertensives and lipid-lowering agents (statins).\n  3. Chronic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).\n  4. Daily fibre supplements.",true,"ALL","18 Years","39 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to evaluate whether eating biscuits made with mature okra flour can help young adults feel fuller (enhance satiety) and change certain blood markers compared to eating standard biscuits.\n\nMature okra is a nutrient-dense agricultural by-product that is often discarded due to its tough texture. For this study, mature okra pods are dried and ground into a flour, which is then used to replace 10% of the wheat flour in a custom biscuit formulation.\n\nParticipants will take part in a single-blind, randomised trial where they will consume either the okra-incorporated biscuits or the standard control biscuits on separate occasions. Researchers will measure participants' perceived fullness over 165 minutes using a visual rating scale. Blood samples will also be collected at specific intervals during this time to evaluate blood glucose levels, appetite-related hormones, and metabolic responses.",[29,30],"Appetite Regulation","Healthy Young Adults",[32,33,34,35],"Satiety response","Blood glucose response","Hormonal change","Metabolomic analysis","RECRUITING","2026-06-03",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":40},"2026-05-15",{"date":44,"type":23},"2026-06-25",{"name":46,"class":47},"Universiti Putra Malaysia","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100635534","sustainable-and-inclusive-use-of-alternative-proteins-in-mediterranean-supply-chains-cipromed-100635534","NCT07553936","Sustainable and Inclusive Use of Alternative Proteins in Mediterranean Supply Chains (CIPROMED)","Circular and Inclusive Use of Alternative Proteins in Mediterranean Supply Chains (CIPROMED)","CIPROMED","Inclusion Criteria:\n\n* Providing signed informed consent,\n* Being between 18 and 65 years of age,\n* Having a body mass index (BMI) within the normal range, defined as between 18.5 and 24.9 kg\u002Fm² or Having a body mass index (BMI) between 25.0 and 34.9 kg\u002Fm², inclusive, corresponding to the overweight category or, at most, class I obesity.\n\nExclusion Criteria:\n\n* Positive and documented history of allergy to legumes, insects, microalgae, shellfish, mollusks, crustaceans, snails, insect venom, house dust mites, or any component (ingredient or additive) present in the food prototypes tested, or a confirmed or suspected diagnosis of Celiac Disease.\n* History of severe allergic reactions to any type of allergen.\n* Pregnancy or Breastfeeding","65 Years",{"count":59,"type":23},40,[26],"This study investigates the effects of foods enriched with alternative protein sources, including edible insects, microalgae, hemp, and legumes, on appetite regulation, satiety, food preferences, and metabolic health in healthy adults and individuals with overweight. The study is part of the CIPROMED project, which aims to support sustainable and circular food systems in the Mediterranean area.\n\nThe study consists of two phases. In the acute phase, participants will consume different protein-enriched bread products in a controlled setting following a randomized crossover design. Each participant will be exposed to multiple test conditions, allowing within-subject comparisons of postprandial responses. Outcomes assessed during this phase include satiety, hunger, food preference, craving, and short-term energy intake, measured using validated scales and dietary assessment tools.\n\nIn the chronic phase, participants will follow structured dietary interventions over a longer period within a Mediterranean dietary framework. Participants will be assigned to different dietary patterns including alternative protein-based foods and control products. This phase aims to evaluate the effects of repeated consumption of alternative protein sources on metabolic parameters, gastrointestinal tolerance, nutritional status, and behavioral responses.\n\nThe study aims to assess the acceptability and physiological effects of alternative protein sources and to compare their impact with that of traditional protein sources commonly used in Mediterranean diets.",[63,64,29,65,66],"Food Preferences","Satiety and Food Intake","Overweight (BMI > 25)","Gut Microbiota",[68,69,70,71,29,72,73,74,75,76,77,66],"Alternative Proteins","Edible Insects","Hemp Protein","Legume Protein","Overweight","Novel Foods","Microalgae (Protein)","Food Acceptability","Satiety","Metabolic Health","2026-04-28",{"date":80,"type":40},"2026-05-04",{"date":82,"type":40},"2026-03-18",{"date":84,"type":23},"2027-01-31",{"name":86,"class":47},"University of Bologna",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":48},"100615618","phase-3-impact-of-semaglutide-withdrawal-on-cardiometabolic-profile-and-physiology-of-energy-balance-recovery-effects-after-semaglutide-termination-100615618","NCT07294950","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.","REST","Inclusion Criteria:\n\n* Men and women with previously diagnosed BMI ≥ 30 kg\u002Fm2 or BMI ≥ 27 kg\u002Fm2 and adiposity-related complications (such as osteoarthritis, nonalcoholic liver disease, sleep apnea, and hypertension) without preexisting cardiovascular disease or type 2 diabetes.\n* Age 18 - 75 years inclusive\n* Ongoing weight-loss treatment consisting of weekly subcutaneous semaglutide at minimum dose of 1 mg\u002Fweekly with documented weight reduction of at least 10% of pre-treatment body weight\n* Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported)\n* Ability to read and understand English\n\nExclusion Criteria:\n\n* Previously diagnosed cardiovascular disease defined as previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease.\n* Currently pregnant or lactating\n* Previously diagnosed type 2 diabetes\n* Use of any other pharmacological treatment for weight-loss\n* Previous surgical treatment for weight loss such as gastric bypass or gastric band\n* Any history of eating disorder\n* Renal dysfunction as evidenced by estimated glomerular filtration rate \\\u003C 25 ml\u002Fmin by CKD-EPI Creatinine Equation\n* New York Heart Association class II-IV heart failure\n* Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \\>2.5X the upper limit of normal\n* Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)\n* Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n* Any other factor likely to limit adherence to the study, in the opinion of the investigators","75 Years",{"count":97,"type":23},98,[99],"PHASE3","Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, its accompanied health benefits could be ameliorated with a gradual reduction in semaglutide. The investigators will study if a gradual reduction of semaglutide is associated with different heart risk profile and hormones involved in energy regulation as compared to immediate treatment cessation.",[102,103,104,29],"Obesity (Disorder)","Weight Change","Blood Pressure Monitoring",[106,107],"Randomized controlled trial","Interventional","2026-02-09",{"date":110,"type":40},"2026-02-11",{"date":112,"type":40},"2026-02-01",{"date":114,"type":23},"2029-05",{"name":116,"class":47},"Mount Sinai Hospital, Canada",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":48},"100484368","exposure-based-cbt-for-avoidantrestrictive-food-intake-in-functional-dyspepsia-100484368","NCT05587127","Exposure-Based CBT for Avoidant\u002FRestrictive Food Intake in Functional Dyspepsia","A Randomized Controlled Trial of Exposure-Based Cognitive Behavioral Treatment for Avoidant\u002FRestrictive Food Intake in Functional Dyspepsia","Inclusion Criteria\n\n* Age at least 18 years at screening visit\n* Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome)\n* Negative upper endoscopy or upper radiographic GI series to rule out structural\u002Forganic cause for FD\n* Avoidant\u002FRestrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for DSM-5; SCID-5 at Screening visit)\n* ≥5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit)\n* Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders)\n* No previous history of CBT for functional dyspepsia or ARFID\n* Computer\u002Finternet webcam access\n* Fluency in English\n* Stable dose for 30 days if on any medication\n\nExclusion Criteria\n\n* Inability to provide informed consent\n* Presence of other conditions that could explain the patient's symptoms by chart:\n\nPyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer\n\n* Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)\n* History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)\n* History of any serious medical condition (e.g., cancer)\n* Use of narcotic analgesics greater than three days per week\n* Current pregnancy or breastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c ≥7%) by chart\n* Intellectual disability by history\n* Current substance\u002Falcohol use disorder within the past month\n* Current\u002Fhistory of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen)\n* Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months)\n* Active suicidal ideation (by MINI-Screen)\n* Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen))\n* Current enteral or parenteral feeding\n* Plans to initiate another psychotherapy or pregnancy in the concurrent study period",{"count":125,"type":23},50,[26],"Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant\u002Frestrictive food intake disorder (ARFID) with weight loss.",[129,130,131,132,29,133,134,135],"Avoidant\u002FRestrictive Food Intake Disorder","Dyspepsia","Feeding and Eating Disorders","Cognitive Behavioral Therapy","Functional Dyspepsia","Post-prandial Distress Syndrome","Behavioral Medicine","2025-09-22",{"date":138,"type":40},"2025-09-25",{"date":140,"type":40},"2022-11-30",{"date":142,"type":23},"2027-05",{"name":144,"class":47},"Massachusetts General Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":17,"sex":18,"minAge":151,"maxAge":95,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100583290","comparison-of-dairy-and-plant-based-alternatives-in-adolescents-and-older-adults-100583290","NCT06874400","Comparison of Dairy and Plant-based Alternatives in Adolescents and Older Adults","Inclusion Criteria:\n\n* Age 14-18 years old (adolescents) or 60-75 years old (older adults)\n* BMI z-score \\>+1SD, \\\u003C+2SD (adolescents) or BMI 25-30 kg\u002Fm2 (older adults)\n* Willing to maintain habitual diet, physical activity pattern, and body weight throughout the study.\n* Willing to maintain current dietary supplement use throughout the study. On study visit days, subject agrees not to take any supplements until dismissal from the Nutrition Intervention Center.\n* Willing to abstain from alcohol consumption for 24hrs prior to all study visits.\n* Willing to avoid vigorous physical activity for 24hrs prior to all study visits.\n* Willing to refrain from cannabis use throughout the entire duration of the study.\n* Willing to refrain from protein supplement use (e.g. protein powder) throughout the entire duration of the study.\n* Understands the study procedures, provides informed consent to participate in the study, and authorizes release of relevant protected health information to the study investigator.\n\nExclusion Criteria:\n\n* Smoking\n* Thyroid problems\n* Lactose intolerance and\u002For allergies, intolerances, or sensitivities to study treatments\n* Previous history of cardiovascular disease, diabetes, liver or kidney disease, inflammatory bowel disease, celiac disease, short bowel syndrome, malabsorptive syndrome, pancreatitis, gallbladder or biliary disease\n* Presence of gastrointestinal disorder or surgeries within the past year.\n* Inability to comply with the experimental procedures and follow our safety guidelines\n* Regular breakfast skipping (\\>3 days a week)\n* On a special diet (e.g. ketogenic, Atkins, high protein) or restrained eaters as identified by a score of \\>20 on the Eating Attitudes Questionnaire\n* Difficulties with eating or swallowing\n* Fasting blood glucose \\>5.6mmol\u002FL measured at screening\n* Uncontrolled hypertension (systolic blood pressure \\>120mmHg, diastolic blood pressure \\>80mmHg) as defined by the average blood pressure measured at screening\n* Weight gain or loss of \\>10lbs in previous three months\n* Consuming prescription or non-prescription drug, herbal or nutritional supplements known to affect outcome of the study as per investigator's judgement","14 Years",{"count":153,"type":23},160,[26],"The purpose of the Dairy vs Plant study is to compare the effects of dairy and plant-based alternative products on blood sugar regulation and nutrient quality in adolescents and older adults. We are inviting healthy, non-diabetic participants aged 14-18 and 60-75, both males and females to participate. The study will take place in the Nutrition Intervention Center located at the Department of Nutritional Sciences, University of Toronto St. George campus. Participants will be asked to come to the Nutrition Intervention Center on 3 separate occasions: once for an in-person screening lasting approximately 30min and 2 times for study visits lasting approximately 2.5 hrs each. The entire study will take a minimum of 2 weeks to complete. You will be asked to fast for 12hrs (overnight) prior to each study visit. You will also be instructed to maintain the same dietary and sleep patterns, refrain from exercise and alcohol consumption the days before the study visits. During these study visits, you will be asked to consume either a dairy or a plant-based alternative product, as well as a pizza meal. You will periodically fill out questionnaires rating your feelings and perceptions and provide blood samples through finger pricks and intravenously through forearm to measure blood sugar, insulin, hormones, and amino acids. You will be compensated for your time and travel expenses.",[157,158,29],"Glycemic Response to Feeding in Healthy Participants","Postprandial Amino Acid Concentrations",[160,161,162,163,164,165,166,167,168,169],"Nutrition","dairy","plant-based foods","glycemic response","appetite","protein","food","adolescents","older adults","overweight","2025-03-07",{"date":172,"type":40},"2025-03-13",{"date":174,"type":23},"2025-04-01",{"date":176,"type":23},"2028-04-01",{"name":178,"class":47},"University of Toronto"]